Zobrazeno 81 - 90
of 275
pro vyhledávání: ''
Publikováno v:
Leukemia. 24:986-991
Specific cytogenetic alterations and changes in DNA methylation are involved in leukemogenesis. Benzene, an established human leukemogen, is known to induce cytogenetic changes through its active metabolites including hydroquinone (HQ), but the speci
Publikováno v:
Leukemia. 24:552-562
Folate cofactors are essential components of one carbon metabolism and are required for the biosynthesis of purines, pyrimidines, serine and methionine. The classical folate antagonist methotrexate (MTX) continues to be a universal component of most
Autor:
Antje Hoering, Saad Z. Usmani
Publikováno v:
Leukemia. 27:2269-2271
Since the year 2000, there has been a continued improvement in survival outcomes for multiple myeloma (MM) patients,1 attributable to the clinical development and inclusion of novel agents in upfront therapy, and improvement in high-dose therapy admi
Autor:
A.A.N. Giagounidis, V Janzen, Ulrich Germing, Detlef Haase, Oliver G. Ottmann, Anne Letsch, Jürgen Krauter, Oliver Leismann, Uwe Platzbecker, Michael Lübbert, Richard F. Schlenk, Andrea Kündgen, H Reinhard, Norbert Gattermann, Gerhard Ehninger, Martin Wermke, K Lieder, Florian Nolte, Katharina Götze, Haifa Kathrin Al-Ali, C Weiss
Publikováno v:
Leukemia. 28:696-698
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
Autor:
Eileen Whyte O’Holleran, Stephen E. Sallan, Donna Neuberg, Lewis B. Silverman, Harvey J. Cohen, Marshall A. Schorin, Kara M. Kelly, Luis A. Clavell, Caroline Laverdière, Peter D. Cole, Cindy L. Schwartz, Bruno Michon, Kristen E. Stevenson, Jane E. O'Brien, Barbara L. Asselin, Ronald D. Barr
Publikováno v:
Leukemia
The Dana-Farber Cancer Institute (DFCI) acute lymphoblastic leukemia (ALL) Consortium has been conducting multi-institutional clinical trials in childhood ALL since 1981. The treatment backbone has included 20-30 consecutive weeks of asparaginase dur
Autor:
Harland N. Sather, James B. Nachman, Stephen P. Hunger, Meenakshi Devidas, Michael E. Trigg, Paul S. Gaynon, William L. Carroll, Anne L. Angiolillo
Publikováno v:
Leukemia
The Children’s Cancer Group enrolled 13,298 young people age < 21 years on one of 16 protocols between 1983 and 2002. Outcomes were examined in three time periods, 1983–1988, 1989–1995, 1996–2002. Over the three intervals, 10-year event-free
Autor:
Stephen P. Hunger, Meenakshi Devidas, Naomi J. Winick, Jeanette Pullen, Wanda L. Salzer, Bruce M. Camitta, William L. Carroll
Publikováno v:
Leukemia
From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies. Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series w
Autor:
Jatin J. Shah, Robert Z. Orlowski
Publikováno v:
Leukemia. 23:1964-1979
Targeting intracellular protein turnover by inhibiting the ubiquitin-proteasome pathway as a strategy for cancer therapy is a new addition to our chemotherapeutic armamentarium, and has seen its greatest successes against multiple myeloma. The first-
Autor:
Wijnand Helfrich, B. ten Cate, Georg H. Fey, M. de Bruyn, Gerwin Huls, Edwin Bremer, Theo Bijma, Douwe F. Samplonius, M. Schwemmlein
Publikováno v:
Leukemia, 23(8), 1389-1397. Nature Publishing Group
Gemtuzumab ozogamicin (GO, Mylotarg) is a targeted therapeutic agent in which an anti-CD33 antibody is chemically coupled to a highly cytotoxic calicheamicin derivative through a hydrolysable linker. GO has improved the treatment outcome for a subgro
Autor:
Isao Hirano, Masato Maekawa, Yoshikazu Sugimoto, Nozomi Yamakage, Kaori Shinjo, Akihiro Takeshita, Kazunori Ohnishi, Takaaki Ono, Ryuzo Ohno, Hitoshi Kiyoi, Tomoki Naoe, Satoki Nakamura, Kazuyuki Shigeno, Tadasu Tobita
Publikováno v:
Leukemia. 23:1329-1336
We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with rituximab, analyzing the quantitative alteration of target molecules, that is, CD20, CD22, CD55 and CD59, in Daudi and Ra